Notice of Marketing Authorization for “RAVICTI^® Oral Liquid 1.1 g/mL” for Urea Cycle Disorders

Notice regarding Designation as an Orphan Drug and Supplemental New Drug Application for Sodium Phenylbutyrate for Designated Intractable Disease "Progressive Familial Intrahepatic Cholestasis (PFIC)"

Notice of Head Office Relocation (Change of Building)